Table 1.

Pharmacokinetics and side effects of dostarlimab.

MOA	Anti PD-1 receptor
Mean Elimination half-life	10–20 days Approximately
Dosing	500 mg IV every 3 weeks, followed by 1000 mg IV every 6 weeks
Side Effects	●Fatigue, asthenia, nausea, diarrhea, anemia, constipation, increased transaminases, increased lipase. ●Vomiting, joint pain, itching, rash, fever and hypothyroidism.
Series adverse events	Sepsis, AKI, UTI, abdominal pain and pyrexia.
Immune mediated adverse reactions	Pneumonitis, colitis, hepatitis, endocrinopathies and nephritis.